SCHEMBL15034962

SCHEMBL15034962

C#Cc1cc2cnc(Nc3ccc(C4=CCNCC4)cc3)nc2n(Cc2nccnc2-c2nccs2)c1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 5/20 0.36
CDK6 Q00534 3/20 0.36
MEN1 O00255 4/20 0.33
USP2 O75604 4/20 0.33
CASP1 P29466 4/20 0.33
KMT2A Q03164 4/20 0.33
HIF1A Q16665 4/20 0.33
CYP1A2 P05177 3/20 0.33
CASP7 P55210 3/20 0.33
HSD17B10 Q99714 2/20 0.33
LMNA P02545 2/20 0.33
ALDH1A1 P00352 1/20 0.33
BRCA1 P38398 2/20 0.33
PAK3 O75914 2/20 0.32
PAK1 Q13153 2/20 0.32
PAK2 Q13177 2/20 0.32
PKN1 Q16512 1/20 0.32
CYP3A4 P08684 1/20 0.32
TSHR P16473 1/20 0.32
JAK3 P52333 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15041769 0.93 CDK4 (0.38) CDK4CDK6MEN1USP2CASP1
SCHEMBL15041732 0.80 FGFR1 (0.39) CDK4CDK6JAK3FGFR1CCNA2
SCHEMBL15036315 0.79 FGFR1 (0.40) CDK4CDK6FGFR1CCNA2FGFR2
SCHEMBL15036198 0.77 CDK4 (0.39) CDK4CDK6JAK3FGFR1CCNA2
SCHEMBL15041544 0.77 CDK4 (0.39) CDK4CDK6JAK3FGFR1CCND1
SCHEMBL15034855 0.76 CDK4 (0.37) CDK4CDK6PAK3PAK1PAK2
SCHEMBL15035073 0.76 CDK4 (0.39) CDK4CDK6JAK3FGFR1CCNA2
SCHEMBL15035931 0.75 CDK4 (0.36) CDK4CDK6JAK3CCNA2CCND1
SCHEMBL15036177 0.74 PTK2 (0.36) CDK4CDK6JAK3FGFR1CCNA2
SCHEMBL15035723 0.73 CDK4 (0.39) CDK4CDK6JAK3FGFR1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130231348-A1 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS AFRAXIS, INC. (US) 2013-09-05 US disclosed
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER AFRAXIS, INC. (US) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231348-A1 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS PAK2, PAK3, PAK5 CDK4 408/4885CDK6 299/4885MEN1 2261/4885
US-20130158043-A1 PAK INHIBITORS FOR THE TREATMENT OF CANCER PAK5, PAK2, PAK6 CDK4 404/4885CDK6 435/4885MEN1 2982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.